natgillin/translations-raw huggingface dataset:
• The manufacturing site Pharmaceutics International Inc in the United States which makes a number of medicines has been found to have several shortcomings in its good manufacturing practice. 
• V proizvodnem obratu družbe Pharmaceutics International Inc v Združenih državah, v katerem proizvajajo več zdravil, je bilo najdenih več pomanjkljivosti pri dobri proizvodni praksi.
In countries where alternatives are available, your doctor will consider putting you on another treatment. 
V državah, v katerih so na voljo druge možnosti zdravljenja, bo zdravnik razmislil o zamenjavi zdravila.
• In patients receiving Ammonaps orally (either as tablets or granules), other phenylbutyratecontaining medicines should be considered instead. 
• Za bolnike, ki prejemajo zdravilo Ammonaps peroralno (v oblik tablet ali zrnc), je treba namesto njega razmisliti o drugih zdravilih, ki vsebujejo fenilbutirat.
Ammonaps should only be used in patients when no alternative treatment is available. 
Zdravilo Ammonaps se sme uporabljati pri bolnikih le, kadar ni na voljo druge možnosti zdravljenja.
• SoliCol D3 (cholecalciferol), a medicine for vitamin D deficiency which is also exclusively produced at Pharmaceutics International Inc but has not yet been marketed in the EU, will not be made available in the EU. 
• SoliCol D3 (holekalciferol), zdravilo za zdravljenje pomanjkanja vitamina D, ki ga prav tako proizvaja izključno družba Pharmaceutics International Inc, vendar v EU še ni na trgu, v EU ne bo na voljo.
Ammonaps granules should only be used in patients who have a feeding tube such as a nasogastric tube or gastrostomy and require the medicine. 
Zdravilo Ammonaps v obliki zrnc se lahko uporablja samo pri bolnikih s hranilno sondo, kot sta nazogastrična sonda ali gastrostoma, ki to zdravilo potrebujejo.
In EU countries where treatment alternatives exist, Ammonaps will be recalled. 
V državah EU, v katerih obstaja druga možnost zdravljenja, bo zdravilo Ammonaps odpoklicano;
• Other Pharmaceutics International Inc medicines have alternative manufacturing sites and therefore their availability is unaffected. 
• Druga zdravila družbe Pharmaceutics International Inc se izdelujejo v drugih proizvodnih obratih, zato njihova razpoložljivost ostaja nespremenjena.
• The medicines Dutasteride Actavis (dutasteride), Lutigest/Lutinus (progesterone), and associated names, are registered to be produced at Pharmaceutics International Inc, but are now 
• proizvodnja zdravil Dutasteride Actavis (dutasterid) in Lutigest/Lutinus (progesteron) in povezana imena je registrirana v družbi Pharmaceutics International Inc, vendar se zdaj izdelujeta v drugih
Ammonaps has been recalled in countries where alternatives are available. 
Zdravilo Ammonaps so v državah, v katerih so na voljo druge možnosti zdravljenja, odpoklicali.
• One of the medicines manufactured at this site is Ammonaps (sodium phenylbutyrate), a medicine to treat urea cycle disorders. 
• Eno od zdravil, ki se izdelujejo v tem obratu, je Ammonaps (natrijev fenilbutirat), zdravilo za zdravljenje motenj v ciklusu sečnine.
• One of the medicines affected, Ammonaps (sodium phenylbutyrate), used to treat inherited metabolic disorders, is considered a critical medicine and remains on the market where there are no alternatives. 
• Eno od zadevnih zdravil, Ammonaps (natrijev fenilbutirat), ki se uporablja za zdravljenje dednih presnovnih motenj, je zdravilo ključnega pomena in ostaja na trgu tam, kjer ni drugih možnosti zdravljenja.
• Other medicines (Dutasteride Actavis (dutasteride), Lutigest/Lutinus (progesterone), and associated names) produced at the site have alternative manufacturing sites and the availability of these medicines is unaffected. 
• Druga zdravila (Dutasteride Actavis (dutasterid), Lutigest/Lutinus (progesteron) in povezana imena), ki se izdelujejo v tem obratu, imajo druga proizvodna mesta, zato njihova razpoložljivost ostaja nespremenjena.
The review was started after a follow-up inspection of the site by the UK medicines regulatory agency (MHRA) and the US FDA. 
Priporočilo je bilo rezultat pregleda dobre proizvodne prakse v družbi Pharmaceutics International Inc. Pregled se je začel po nadaljnjem inšpekcijskem pregledu v proizvodnem obratu, ki sta ga opravili regulativna agencija Združenega kraljestva (MHRA) in agencija ZDA za zdravila in prehrano (FDA).
The manufacturing site had insufficient measures in place to reduce the risk that traces of one medicine could be transferred to another (cross-contamination). 
Ukrepi za zmanjševanje tveganja za prenos sledov enega zdravila v drugega (navzkrižne kontaminacije) v tem obratu niso bili zadostni.
• Ammonaps, a medicine for treating urea cycle disorders which is exclusively manufactured at Pharmaceutics International Inc, remains available where there are no treatment alternatives. 
• Ammonaps, zdravilo za zdravljenje motenj v ciklusu sečnine, ki ga proizvaja izključno družba Pharmaceutics International Inc, ostaja na voljo, kadar ni drugih možnosti zdravljenja.
Ammonaps may still be supplied where no alternatives are available 
Zdravilo Ammonaps se lahko še naprej dobavlja, kadar ni na voljo druge možnosti zdravljenja.
manufactured at alternative registered manufacturing sites. 
proizvodnih obratih.
This conclusion was accepted. 
Ta zaključek je bil sprejet.
In June 2006 a Mutual Recognition Procedure started with The Netherlands as Reference Member State and six Concerned Member States. 
Junija 2006 se je pričel postopek medsebojnega priznavanja z Nizozemsko kot referenčno državo članico ter šestimi zadevnimi državami članicami.
The CVMP Opinion was adopted on 18 April 2007 and the subsequent Commission Decision on 10 July 2007. 
Mnenje CVMP je bilo sprejeto 18. aprila 2007, s tem povezana odločba Komisije pa 10. julija 2007.
London, June 2008 EMEA/532222/2007 - Rev.1 
London, junij 2008 EMEA/532222/2007 - Rev.1
The CVMP during its meeting of December 2006 started a referral procedure under Article 33(4) of Directive 2001/82/EC as amended for Enurace 50. 
CVMP je med svojim zasedanjem decembra 2006 pričel napotitveni postopkom v skladu s členom 33(4) Direktive 2001/82/ES, kakor je bila spremenjena, za zdravilo Enurace 50.
France and Italy could not agree to the granting of a marketing authorisation as they considered there were potentially serious risks for animal health. 
Francija in Italija se nista strinjali z odobritvijo dovoljenja za promet, saj sta menili, da obstajajo možna resna tveganja za zdravje živali.
The CVMP, therefore, concluded that the benefit/risk for this product was favourable. 
CVMP je zato zaključil, da je razmerje med koristmi in tveganji za to zdravilo ugodno.
EMEA/532222/2007 - Rev.1 
EMEA/532222/2007 - Rev.1-SL
OPINION FOLLOWING AN ARTICLE 33 (4) REFERRAL FOR ENURACE 50 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 33(4) ZA ZDRAVILO ENURACE 50
The Marketing Authorisation Holder was requested to provide all supporting data to justify a positive benefit/risk ratio for the treated animal. 
Od imetnika dovoljenja za promet z zdravilom je bilo zahtevano, da predloži vse podporne podatke, da bi upravičil pozitivno razmerje med koristmi in tveganji za zdravljeno žival.
The matter was referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures CMD(v) and subsequently to the Committee for Medicinal Products for Veterinary Use. 
Zadeva je bila napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirane postopke za zdravila za uporabo v veterinarski medicini (CMD(v)) in nato na Odbor za zdravila za uporabo v veterinarski medicini.
These results were convincing when compared to the 20 % placebo treated animals that became continent in study ACE129801. 
Ti rezultati so bili prepričljivi pri primerjavi z 20 % živali iz študije ACE129801, ki so bile zdravljene s placebom in postale kontinentne.
In response to the questions related to toxicity, the applicant argued that due to the pharmacologic effect of ephedrine and the individual variation in receptor density no safety margin could be determined and increasing doses will be associated to increased intensity and frequency of well known adverse effects. 
V odgovoru na vprašanja, povezana s toksičnostjo, je predlagatelj navedel, da zaradi farmakološkega učinka efedrina in individualne variacije gostote receptorjev ni bilo mogoče določiti meje varnosti, višanje odmerka pa bo povezano z intenzivnostjo in pogostostjo dobro poznanih neželenih učinkov.
However, the study where Enurace 50 is compared to Propaline (ACE129802) is convincing although a non-inferiority analysis has not been performed. 
Kljub vsemu je študija, v kateri so zdravilo Enurace 50 primerjali z zdravilom Propaline (ACE129802), prepričljiva, čeprav analiza enakovrednosti zdravil ni bila izvedena.
At the recommended dose level, which according to the suggested SPC should be individually adjusted, safety is ensured to a reasonable level. 
Pri priporočenem odmerku, ki ga je treba v skladu s predlaganim povzetkom glavnih značilnosti zdravila individualno prilagoditi, je raven varnosti primerna.
Enurace 50 is a tablet formulation containing ephedrine as active ingredient and is indicated for treatment of urinary incontinence caused by urethral sphincter mechanism incompetence in ovariohysterectomised dogs. 
Zdravilo Enurace 50 je pripravek v obliki tablet, ki vsebuje zdravilno učinkovino efedrin in je indicirano za zdravljenje urinarne inkontinence, ki je posledica nepravilnega delovanja sfinkterskega mehanizma uretre pri psicah po ovariohisterektomiji.
Efficacy data are connected to several shortcomings and the amount of data available is sparse. 
Podatki o učinkovitosti imajo več pomanjkljivosti, poleg tega jih je malo.
Although toxicity data for the target animal may be scarce, the adverse effects connected to ephedrine treatment are well known from human use, and the applicant had provided some post-marketing information regarding the use in dogs. 
Čeprav utegnejo biti podatki o toksičnosti za ciljno žival skromni, so neželeni učinki, povezani z zdravljenjem z efedrinom, dobro znani iz uporabe pri ljudeh, predlagatelj pa je predložil nekaj informacij v zvezi z uporabo pri psih po izdaji dovoljenja za promet.
The raw outcome shows good effect in both test and control groups, an effect that might be somewhat higher in treatment naïve animals. 
Neobdelani rezultati izkazujejo dober učinek v testni in kontrolni skupini, ta učinek pa utegne biti pri zdravljenju predhodno nezdravljenih živali še nekoliko boljši.
France considered the benefit/risk analysis unfavourable for the animal when the adverse effects were weighed against the potential benefits of effective treatment of incontinence. 
Francija je menila, da je analiza koristi in tveganj, če neželene učinke primerjamo z možnimi koristmi učinkovitega zdravljenja inkontinence, za žival neugodna.
With regard to the related to cardiovascular diseases, the SPC is to be modified under section 4.5 to include the sentence “the dog's cardiovascular functionality should be carefully assessed before the start of the treatment with Enurace 50 and it should be periodically monitored during the treatment”. 
Glede srčno-žilnih bolezni je treba poglavje 4.5 povzetka glavnih značilnosti zdravila dopolniti s stavkom „Pred začetkom zdravljenja z zdravilom Enurace 60 je treba natančno ugotoviti deloavnje srca in ožilja ter to med zdravljenjem redno spremljati“.
Italy could have accepted the application but with revised wording in the SPC. 
Italija bi vlogo sprejela, vendar s popravljenim besedilom povzetka glavnih značilnosti zdravila.
Date of latest renewal: 19 November 2014 
Datum prve odobritve: 15. marec 2010 Datum zadnjega podaljšanja: 19. november 2014
Do not stop the treatment unless your doctor tells you so. 
Ne prekinite zdravljenja, razen če vam tega ne odredi zdravnik.
Some other medicines may influence the use of DuoPlavin or vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila DuoPlavin in obratno.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/ 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
The safety and efficacy of DuoPlavin in children and adolescents under 18 years old have not been established. 
Varnost in učinkovitost zdravila DuoPlavin pri otrocih in mladostnikih mlajših od 18 let nista ugotovljeni.
Refer to local requirements for disposal. 
Upoštevajte lokalne zahteve za odlaganje.
Side effects with frequency not known (frequency cannot be estimated from the available data): 
Možni neželeni učinki, katerih pogostnost ni znana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti):
Following toxic doses (10 20 g), the plasma half-life may be increased to over 20 hours. 
Po toksičnih odmerkih (10 20 g) se lahko razpolovni čas v plazmi podaljša na več kot 20 ur.
• You should tell your doctor - if a surgery (including dental) is planned. 
• morate povedati zdravniku: - če imate predvideno kakšno operacijo (vključno z zobozdravstvenim posegom).
DuoPlavin is not intended for use in children or adolescents less than 18 years of age. 
Zdravilo DuoPlavin ni namenjeno uporabi pri otrocih in mladostnikih, mlajših od 18 let.
At low concentrations (<100 micrograms/ml), approximately 90% of salicylic acid is bound to albumin. 
Pri nizkih koncentracijah (< 100 g/ml) je približno 90 % salicilne kisline vezane na albumin.
Depending on your condition, your doctor will determine the length of time for which you need to take DuoPlavin. 
Zdravnik bo glede na vaše stanje določil, koliko časa morate jemati zdravilo DuoPlavin.
DuoPlavin is not recommended in this population. 
Uporaba zdravila DuoPlavin se v tej populaciji ne priporoča.
Interactions with the following medicinal products have been reported with ASA: 
Opisane so interakcije med ASA in naslednjimi zdravili:
** Information related to clopidogrel with frequency “not known”. 
** Informacije v povezavi s klopidogrelom s pogostnostjo “ni znana”.
The European Medicines Agency has waived the obligation to submit the results of studies with DuoPlavin in all subsets of the paediatric population in the treatment of coronary atherosclerosis (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveznosti po predložitvi rezultatov študij zdravila DuoPlavin pri vseh podskupinah pediatrične populacije za zdravljenje koronarne ateroskleroze (glejte poglavje 4.2 za informacije o pediatrični uporabi).
DuoPlavin should not be used during the first two trimesters of pregnancy unless the clinical condition of the woman requires treatment with clopidogrel/ASA. 
Zdravilo DuoPlavin se ne sme uporabljati v prvih dveh trimesečjih nosečnosti, razen če klinično stanje nosečnice ne zahteva terapije s klopidogrelom / ASA.
In patients with ST segment elevation acute myocardial infarction: Therapy should be started as early as possible after symptoms start and continued for at least four weeks. 
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST spojnice: zdravljenje je potrebno začeti čim prej po nastopu simptomov in z njim nadaljevati vsaj štiri tedne.
Patients should inform physicians and dentists that they are taking DuoPlavin before any surgery is scheduled and before any new medicinal product is taken. 
Bolniki morajo obvestiti zdravnika in zobozdravnika, da jemljejo klopidogrel, pred vsakim načrtovanjem kirurškega posega in preden vzamejo katerokoli novo zdravilo.
Due to the presence of both components of the medicinal product, DuoPlavin is contraindicated in case of: 
Zaradi vsebnosti obeh učinkovin v zdravilu, je zdravilo DuoPlavin kontraindicirano v primeru:
If patients must temporarily stop antiplatelet therapy, DuoPlavin should be discontinued 7 days prior to surgery. 
Če mora bolnik začasno prekiniti antiagregacijsko terapijo morate zdravilo DuoPlavin ukiniti 7 dni pred kirurškim posegom.
If acetylsalicylic acid is used by a woman attempting to conceive, or until the 24th amenorrhea week (5th month of pregnancy), the dose should be kept as low and duration of treatment as short as possible. 
Če acetilsalicilno kislino uporablja ženska, ki poskuša zanositi, ali do 24. tedna amenoreje (5. meseca nosečnosti), mora biti odmerek čim manjši, zdravljenje pa čim kratkotrajnejše.
What DuoPlavin is and what it is used for 
Kaj je zdravilo DuoPlavin in za kaj ga uporabljamo
If the use of DuoPlavin is discontinued, patients may benefit with continuation of one antiplatelet medicinal product. 
V primeru prenehanja uporabe zdravila DuoPlavin lahko bolniku koristi nadaljevanje uporabe enega antiagregacijskega zdravila.
If you experience prolonged bleeding when taking DuoPlavin If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
Če doživite podaljšanje krvavitve v času jemanja zdravila DuoPlavin Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se vam krvavitev ustavi.
A pharmacodynamic interaction between DuoPlavin and heparin is possible, leading to increased risk of bleeding. 
Farmakodinamična interakcija med zdravilom DuoPlavin in heparinom je možna in vodi do povečanega tveganja za krvavitev.
Driving and using machines DuoPlavin should not affect your ability to drive or to use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo DuoPlavin ne bi smelo vplivati na vašo sposobnost za vožnjo ali upravljanje strojev.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
• preobčutljivosti za zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1,
Other medicines and DuoPlavin 
Druga zdravila in zdravilo DuoPlavin
What you need to know before you take DuoPlavin 
Kaj morate vedeti, preden boste vzeli zdravilo DuoPlavin
DuoPlavin has no or negligible influence on the ability to drive and use machines. 
Zdravilo DuoPlavin nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
This randomized, open-label trial included ACS patients requiring PCI. 
To randomizirano, odprto preskušanje je vključilo bolnike z AKS, ki so potrebovali PKI.
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics. 
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥ 60 let (26 % ≥ 70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel plus ASA group and 363 (5.8%) in the ASA group]. 
Ta korist je bila v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom in ASA, in 363 (5,8 %) v skupini z ASA].
Apart from the specific medicinal product interaction information described above, interaction studies with DuoPlavin and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen navedenih informacij o specifičnih interakcijah z zdravili, študij o interakcijah zdravila DuoPlavin in nekaterih zdravil, ki jih pogosto uporabljajo bolniki z aterotrombotično boleznijo ni bilo.
It also contains: lactose and hydrogenated castor oil. 
Vsebuje tudi laktozo in hidrogenirano ricinusovo olje.
Salicylic acid in DuoPlavin has a plasma half-life of approximately 2 hours. 
Salicilna kislina iz zdravila DuoPlavin ima plazemski razpolovni čas približno 2 uri.
Until the 24th amenorrhea week (5th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary. 
Do 24. tedna amenoreje (5. meseca nosečnost) se acetilsalicilne kisline ne sme uporabljati, če ni nujno potrebno.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking DuoPlavin. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti zdravnika ali farmacevta, preden vzamete zdravilo DuoPlavin.
A patient with poor metaboliser status will possess two loss-offunction alleles as defined above. 
Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
Breast-feeding should be discontinued during treatment with DuoPlavin. 
Dojenje je med zdravljenjem z zdravilom DuoPlavin potrebno prekiniti.
DuoPlavin prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular). 
Zdravilo DuoPlavin podaljša čas krvavitve in ga je potrebno previdno uporabljati pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne).
No clinical data on exposure to DuoPlavin during pregnancy are available. 
Kliničnih podatkov o izpostavljenosti zdravilu DuoPlavin v nosečnosti ni na voljo.
• the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labour. 
• mater in novorojenčka na koncu nosečnosti: - možnemu podaljšanju časa krvavitve, antiagregacijskemu učinku, ki se lahko pojavi celo po zelo majhnih odmerkih, - zavrtju krčenja maternice in zaradi tega odloženemu ali podaljšanemu porodu.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela med nosečnostjo ne uporabljate.
Therefore, this combination should be used with caution in patients taking low dose ASA for cardioprotection . 
Zato je to kombinacijo treba uporabljati previdno pri bolnikih, ki jemljejo nizke odmerke acetilsalicilne kisline za zaščito srca.
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. 
Podatki epidemioloških študij kažejo večje tveganje spontanih splavov, malformacij srca in gastroshize po uporabo zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
Adverse reactions that occurred with clopidogrel alone, with ASA alone or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below. 
Neželeni učinki, zabeleženi samo s klopidogrelom, samo z ASA ali s klopidogrelom v kombinaciji z ASA v kliničnih študijah ali opisani spontano, so našteti v spodnji tabeli.
- if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools). 
- če imate bolečine v želodcu ali trebuhu ali krvavitev v želodec ali črevo (rdeče blato ali črno blato).
• Severe renal impairment (creatinine clearance <30 ml/min). 
• pri bolnikih s hudo okvaro ledvic (očistek kreatinina <30 ml/min),
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, France 
1, Rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, Francija
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. 
Morda vam je zdravnik za zdravljenje vaše bolezni v zamašeno ali zoženo arterijo namestil žilno opornico ("stent"), da bi obnovil ustrezen pretok krvi.
DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). 
Zdravilo DuoPlavin je indicirano za sekundarno preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih, ki že jemljejo klopidogrel in acetilsalicilno kislino (ASA).
Store below 25C. 
Shranjujte pri temperaturi do 25C.
Minor GI symptoms, such as dyspepsia, are common and can occur anytime during therapy. 
Manj izraziti gastrointestinalni simptomi npr. dispepsija, so sicer pogosti in se lahko pojavijo kadarkoli med zdravljenjem.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure. 
Zelo redko so po uporabi klopidogrela poročali o trombotični trombocitopenični purpuri (TTP), ki se je včasih pojavila že po kratki izpostavljenosti.